Texas MPN Workshop 2021 | The current treatment landscape for indolent systemic mastocytosis
Prithviraj Bose, MBBS, MD Anderson Cancer Center, Houston, TX, gives an overview of the current treatment landscape for indolent systemic mastocytosis, highlighting mainstay agents such as proton pump inhibitors, mast cell stabilizers, and leukotriene blockers. Dr Bose also comments on the importance of monitoring bone density. This interview took place at the Texas MPN Workshop: Second Annual Workshop and Meeting in 2021.
Transcript (edited for clarity)
Currently, indolent systemic mastocytosis is treated with a variety of agents that really seek to block the various mediators driving the symptoms of the disease. And so, these include things from antihistamines, both H1 and H2 blockers, to proton pump inhibitors and mast cell stabilizers, sometimes leukotriene blockers, aspirin, as well as in some cases you may even need anti-IgE therapy with omalizumab, which is particularly helpful for recurrent, unexplained anaphylaxis...
Currently, indolent systemic mastocytosis is treated with a variety of agents that really seek to block the various mediators driving the symptoms of the disease. And so, these include things from antihistamines, both H1 and H2 blockers, to proton pump inhibitors and mast cell stabilizers, sometimes leukotriene blockers, aspirin, as well as in some cases you may even need anti-IgE therapy with omalizumab, which is particularly helpful for recurrent, unexplained anaphylaxis.
I would say the mainstays are the H1 and H2 blockers, the proton pump inhibitors, the mast cell stabilizers, and the leukotriene blockers. Now, I will add that every patient should have epinephrine on hand, an EpiPen on hand, for anaphylactic, anaphylactoid reactions. And then finally, bone density is important. These patients can become osteopenic or osteoporotic, and it’s important to pay attention to that with bisphosphonates, calcium, vitamin D, et cetera.
Read more...
Disclosures
Prithviraj Bose, MBBS, has received honoraria from Incyte, Celgene, BMS, CTI BioPharma, Sierra Oncology, Novartis, Blueprint Medicines and Kartos; and has received research support from Incyte, Celgene, BMS, CTI BioPharma, Constellation, Kartos, Blueprint Medicines, Astellas, Pfizer, Promedior and NS Pharma.
